

## AWHONN PRACTICE ALERT

AWHONN Practice alerts provide a timely response to practice issues that may include but are not limited to variations in practice, supply chain demands, and inconsistent guidelines. Using current evidence-based literature, the practice alert will identify the issue and associated risks, recommendations, and benefits of strategies for nurses, and appropriate references to guide practitioners in a timely manner.

**Date:** January 28, 2024

**Reason for Alert:** Administration of Arexvy, the GSK RSV vaccine that is not FDA approved for pregnant persons, has been reported.

**Potential risks of the stated issue:** Patient safety due to lack of pregnancy indication and potential lack of prevention of RSV in newborns.

### Recommendations for practice:

- **Pfizer RSV Vaccine (Absryvo)** is the only recommended RSV vaccine for pregnant patients from 32 through 36 weeks” gestation.
  - Include “**Pregnancy Indication-Pfizer RSV vaccine (Abrysvo) only**” on prescriptions for pharmacies.
  - Locate pharmacies that administer the Pfizer RSV vaccination (Abrysvo) at the nearest location to the pregnant patient by using the following location finder resource: [pfizervax.com](https://pfizervax.com)
- D. Meaney-Delman (personal communication, December 19, 2023)
- The shelf life for Pfizer Abrysvo is **24 months with storage at standard refrigerator temperatures between 2-8 C**. This means that some vaccines can be stored and used next year, thus reducing the risk of wasting vaccines.

**Benefits of recommendations:** Increase patient safety and protection of RSV in pregnant patients and newborns.

**References:** Center for Disease Control and Prevention (2024). National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases The National Respiratory and Enteric Virus Surveillance System (NREVSS): RSV National Trends. <https://www.cdc.gov/surveillance/nrevss/rsv/natl-trend.html>